The global T-cell Lymphoma Market is estimated to be valued at US$ 1961.64 Mn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
T-cell Lymphoma refers to a type of blood cancer that develops from mature white blood cells called T lymphocytes. The diseases affecting T-cells include mycosis fungoides and anaplastic large cell lymphoma. T-cell Lymphoma treatments available in the market help patients fight the disease with targeted therapies like monoclonal antibodies, immunotherapy and precision medicines.
Market key trends:
One of the key trends fueling the growth of T-cell Lymphoma market is increasing adoption of advanced therapies like genetically engineered T-cells. Genetically engineered T-cells involve modifying a patient’s own T-cells to recognize and attack cancer cells through gene therapy techniques. These cells are extracted from the patient's blood and modified in the laboratory to express a gene that programs the T-cells to target specific proteins on the patient's cancer cells. Once reinfused into the patient's bloodstream, the modified T-cells work to find and destroy cancer cells expression the target protein. The treatment provides more targeted and personalized approach for T-cell Lymphoma patients.
The global T-cell lymphoma market is segmented on the basis of type and therapy. Based on type, the market is segmented into peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and anaplastic large cell lymphoma. The peripheral T-cell lymphoma segment dominates the market owing to increasing prevalence rates. Based on therapy, the market is categorized into chemotherapy, targeted therapy, immunotherapy, and bone marrow transplant. The chemotherapy segment accounts for the largest market share due to high adoption rates and cost-effectiveness.
The global T-Cell Lymphoma Market Share is expected to witness high growth, exhibiting CAGR of 9.8% over the forecast period, due to increasing incidence of lymphoma.
North America dominates the global T-cell lymphoma market owing to growing cases and increasing healthcare expenditure. Asia Pacific is expected to witness the fastest growth over the forecast period due to rapidly improving healthcare infrastructure and rising medical tourism.
Key players operating in the T-cell lymphoma market are F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.